Results 41 to 50 of about 2,242,189 (260)

Italian randomized trial among womenwith histerectomy: tamoxifen and hormone-dependent breast cancer in hight-risk women [PDF]

, 2003
Tamoxifen improves outcome in women with breast cancer and reduces the incidence of estrogen receptor-positive (ER+) breast tumors in prevention trials. Tamoxifen use is associated with an increased risk of potentially serious adverse events, principally
MAISSONEUVE P, ROTMENSZ N, VERONESI U, PAGNI, Paola, COSTA A, Italian Tamoxifen Study Group:   +5 more
core   +1 more source

Leishmania is not prone to develop resistance to tamoxifen

International Journal for Parasitology: Drugs and Drug Resistance, 2015
Tamoxifen, an antineoplastic agent, is active in vitro and in vivo against the parasitic protozoa Leishmania. As part of our efforts to unravel this drug's mechanisms of action against the parasite and understand how resistance could arise, we tried to select tamoxifen-resistant Leishmania amazonensis.
Adriano C. Coelho, Cristiana T. Trinconi, Luisa Senra, Jenicer K.U. Yokoyama-Yasunaka, Silvia R.B. Uliana   +4 more
openaire   +3 more sources

CD63+ Cancer‐Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR‐22

Advanced Science, 2020
Tamoxifen remains the most effective treatment for estrogen receptor α (ERα)‐positive breast cancer. However, many patients still develop resistance to tamoxifen in association with metastatic recurrence, which presents a tremendous clinical challenge ...
Yuan Gao, Xiaoju Li, Cheng Zeng, Chenlin Liu, Qiang Hao, Weina Li, Kuo Zhang, Wangqian Zhang, Shuning Wang, Huadong Zhao, Dong Fan, Meng Li, Yingqi Zhang, Wei Zhang, Cun Zhang   +14 more
doaj   +1 more source

Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway

Translational Oncology, 2020
Tamoxifen is a successful endocrine therapy drug for estrogen receptor–positive (ER+) breast cancer. However, resistance to tamoxifen compromises the efficacy of endocrine treatment.
Yijie Fu, Zhu Wang, Chuanxu Luo, Yu Wang, Yanping Wang, Xiaorong Zhong, Hong Zheng   +6 more
doaj   +1 more source

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer [PDF]

, 2010
Tamoxifen is the most widely prescribed anti-estrogen treatment for patients with estrogen receptor (ER)-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may ...
Liang, Liang, J Michael Dixon, Muir, Morwenna, David A Cameron, Walker, Graeme, Sims, Andrew H., Morwenna Muir, Liang Liang, Muir, Morwenna; id_orcid, Langdon, Simon P., Dixon, J. Michael, Sims, Andrew, Taylor, Karen J., Dana Faratian, Graeme Walker, Cameron, David A., Simon P Langdon, Dixon, Mike, Karen J Taylor, Taylor, Karen J, Harrison, David J, Barbara Kuske, David J Harrison, Cameron, David A, Faratian, Dana, Kuske, Barbara, Andrew H Sims, Langdon, Simon P, Harrison, David J.   +28 more
core   +2 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.

PLoS ONE, 2014
Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, most breast tumors develop tamoxifen resistance and are eventually refractory to tamoxifen therapy.
Li Yin, Xin-Tian Zhang, Xiu-Wu Bian, Yu-Ming Guo, Zhao-Yi Wang   +4 more
doaj   +1 more source

Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.

PLoS ONE, 2016
AimThe estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance.
Sara Alkner, Pär-Ola Bendahl, Anna Ehinger, Kristina Lövgren, Lisa Rydén, Mårten Fernö   +5 more
doaj   +1 more source

MIR497HG‐Derived miR‐195 and miR‐497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer

Advanced Science, 2023
Tamoxifen is commonly used for the treatment of patients with estrogen receptor‐positive (ER+) breast cancer, but the acquired resistance to tamoxifen presents a critical challenge of breast cancer therapeutics.
Yao Tian, Zhao‐Hui Chen, Peng Wu, Di Zhang, Yue Ma, Xiao‐Feng Liu, Xin Wang, Dan Ding, Xu‐Chen Cao, Yue Yu   +9 more
doaj   +1 more source

Interaction of tamoxifen with the multidrug resistance P-glycoprotein [PDF]

British Journal of Cancer, 1995
Tamoxifen is an anti-oestrogen which is currently being assessed as a prophylactic for women at high risk of breast cancer. Taxoxifen has also been shown to reverse multidrug resistance in P-glycoprotein (P-gp)-expressing cells, although the mechanism of action is unknown. In this study we demonstrate that tamoxifen interacts directly with P-gp. Plasma
R, Callaghan, C F, Higgins
openaire   +2 more sources